Metabolic Syndrome Risk Factors | Tirzepatide 5Â mg | Tirzepatide 10Â mg | Tirzepatide 15Â mg | Comparator | ||||
---|---|---|---|---|---|---|---|---|
Baseline | Primary Endpoint | Baseline | Primary Endpoint | Baseline | Primary Endpoint | Baseline | Primary Endpoint | |
SURPASS-4 ± MET ± SGLT2i ± SU vs iGlar, N, yes | 156 | 157 | 155 | 466 | ||||
 ≥ 3 Risk Factors | 128 (82.1) | 91 (58.3) | 141 (89.8) | 96 (61.1) | 140 (90.3) | 84 (54.2) | 396 (85.0) | 392 (84.1) |
WC > 102 cm (M), > 89 cm (F) | 124 (79.5) | 100 (64.1) | 129 (82.2) | 96 (61.1) | 128 (82.6) | 91 (58.7) | 359 (77.0) | 385 (82.6) |
FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 156 (100.0) | 129 (82.7) | 157 (100.0) | 133 (84.7) | 155 (100.0) | 119 (76.8) | 466 (100.0) | 460 (98.7) |
SBP > 130 mmHg or DBP > 85 mmHg | 96 (61.5) | 76 (48.7) | 107 (68.2) | 85 (54.1) | 107 (69.0) | 81 (52.3) | 296 (63.5) | 333 (71.5) |
Triglycerides > 150 mg/dL | 93 (59.6) | 68 (43.6) | 82 (52.2) | 54 (34.4) | 95 (61.3) | 51 (32.9) | 248 (53.2) | 230 (49.4) |
HDL < 40 mg/dL (M), < 50 mg/dL (F) | 92 (59.0) | 77 (49.4) | 102 (65.0) | 77 (49.0) | 94 (60.6) | 70 (45.2) | 279 (59.9) | 261 (56.0) |
SURPASS-4 ± MET ± SGLT2i ± SU vs iGlar, N, no | 117 | 119 | 119 | 404 | ||||
 ≥ 3 Risk Factors | 99 (84.6) | 68 (58.1) | 101 (84.9) | 67 (56.3) | 97 (81.5) | 57 (47.9) | 331 (81.9) | 325 (80.4) |
WC > 102 cm (M), > 89 cm (F) | 98 (83.8) | 74 (63.2) | 98 (82.4) | 67 (56.3) | 98 (82.4) | 67 (56.3) | 315 (78.0) | 324 (80.2) |
FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 117 (100.0) | 98 (83.8) | 119 (100.0) | 94 (79.0) | 119 (100.0) | 74 (62.2) | 403 (99.8) | 383 (94.8) |
SBP > 130 mmHg or DBP > 85 mmHg | 73 (62.4) | 58 (49.6) | 73 (61.3) | 70 (58.8) | 72 (60.5) | 57 (47.9) | 264 (65.3) | 276 (68.3) |
Triglycerides > 150 mg/dL | 61 (52.1) | 44 (37.6) | 64 (53.8) | 38 (31.9) | 56 (47.1) | 41 (34.5) | 203 (50.2) | 186 (46.0) |
HDL < 40 mg/dL (M), < 50 mg/dL (F) | 64 (54.7) | 53 (45.3) | 80 (67.2) | 53 (44.5) | 74 (62.2) | 54 (45.4) | 230 (56.9) | 205 (50.7) |